Could a Low-Dose seizure drug quiet Parkinson's psychosis?
NCT ID NCT05824728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether AGB101, a low-dose seizure medication, can reduce hallucinations and delusions in people with Parkinson's disease. About 30 adults aged 40-85 will take the drug and a placebo at different times, with brain scans and questionnaires to track changes. The goal is to see if it safely eases psychotic symptoms without curing the underlying disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE PSYCHOSIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.